Avasimibe
Suppliers
Names
[ CAS No. ]:
166518-60-1
[ Name ]:
Avasimibe
[Synonym ]:
2,6-Diisopropylphenyl [(2,4,6-triisopropylphenyl)acetyl]sulfamate
Sulfamic acid, N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester
[2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate
2,6-di(propan-2-yl)phenyl {[2,4,6-tri(propan-2-yl)phenyl]acetyl}sulfamate
Avasimibe
CI-1011
Chemical & Physical Properties
[ Density]:
1.1±0.1 g/cm3
[ Melting Point ]:
178-180° (Lee); mp 169.5-170.4° (Dozeman)
[ Molecular Formula ]:
C29H43NO4S
[ Molecular Weight ]:
501.721
[ Exact Mass ]:
501.291290
[ PSA ]:
80.85000
[ LogP ]:
9.34
[ Appearance of Characters ]:
white to tan
[ Index of Refraction ]:
1.529
[ Storage condition ]:
room temp
[ Water Solubility ]:
DMSO: ≥40mg/mL
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- CY1482550
- CHEMICAL NAME :
- Benzeneacetamide, N-((2,6-bis(1-methylethyl)phenoxy)sulfonyl)-2,4,6-tri s(1-methylethyl)-
- CAS REGISTRY NUMBER :
- 166518-60-1
- LAST UPDATED :
- 199712
- DATA ITEMS CITED :
- 1
- MOLECULAR FORMULA :
- C29-H43-N-O4-S
- MOLECULAR WEIGHT :
- 501.79
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 137 gm/kg/13W-C
- TOXIC EFFECTS :
- Behavioral - food intake (animal) Skin and Appendages - hair Nutritional and Gross Metabolic - weight loss or decreased weight gain
- REFERENCE :
- FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 36(1, Pt 2),274,1997
Safety Information
[ RIDADR ]:
NONH for all modes of transport
[ HS Code ]:
2935009090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2935009090
[ Summary ]:
2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%
Articles
Pathophysiol. Haemost. Thromb. 36(1) , 9-17, (2007)
The ability to modify the enzymatic processes involved in promoting atherosclerotic plaque disruption and to serially monitor atherosclerotic evolution could provide novel information in the managemen...
J. Nucl. Med. 52(9) , 1369-77, (2011)
The metabolic syndrome affects 25% of the U.S. population and greatly increases the risk of diabetes and coronary artery disease (CAD). We tested the hypothesis that the metabolic syndrome is associat...
Eur. J. Pharmacol. 451(1) , 11-7, (2002)
Evidence suggests that the inhibition of both acyl-CoA:cholesterol acyltransferase and hydroxymethyl glutaryl-CoA reductase causes a synergistic direct antiatherosclerotic effect on the vessel wall. T...